BioNTech’s €16.8 Billion Cash Pile Funds $1 Billion Buyback as Cancer Data Looms

The numbers tell a stark story of transition. BioNTech’s first-quarter revenue slumped to €118.1 million from €182.8 million a year earlier, while its net loss ballooned to €531.9 million — or €494.6 million on an adjusted basis, equating to €1.95 per share. Yet the German biotech group is not retreating. Instead, it is spending aggressively on its future.

Research and development costs surged to €557 million in the quarter, driven by immuno-oncology programmes centred on the drug candidates Pumitamig and Gotistobart, alongside expenses from the 2025 acquisitions of BioNTech China and CureVac. An impairment charge on an intangible asset added to the bill.

The COVID vaccine business, once the company’s lifeblood, continues to wither. BioNTech and Pfizer recently halted a large US vaccine study — not over safety concerns, but because stringent enrolment criteria excluded more than 80% of candidates during pre-screening, making the target of 25,000 to 30,000 healthy adults unattainable. From the end of 2026, Pfizer will take over all vaccine production.

A $1 Billion Vote of Confidence

Against this backdrop, the board has authorised a share buyback programme for American Depositary Shares worth up to $1 billion over the next twelve months, representing roughly 4.2% of outstanding shares. Chief Financial Officer Ramón Zapata framed the move as a disciplined capital allocation strategy that underscores management’s confidence in the long-term growth trajectory.

Should investors sell immediately? Or is it worth buying BioNTech?

The repurchase will be funded entirely from existing cash reserves, which stood at a hefty €16.8 billion as of March 31. That war chest gives BioNTech ample room to finance its oncology pivot while returning capital to shareholders.

The market, however, remains cautious. The stock currently trades at €79.90 — or €79.25 according to some data feeds — roughly 22% below its 52-week high of €101.90. Over the past seven days, the shares have shed nearly 10% and now sit comfortably below their 50-day moving average.

Six Data Catalysts on the Horizon

Management is sticking with its full-year guidance, forecasting revenue between €2.0 billion and €2.3 billion for 2026. The credibility of that outlook hinges almost entirely on the oncology pipeline.

The first major test arrives at the American Society of Clinical Oncology (ASCO) annual meeting, running from May 29 to June 2. BioNTech will unveil Phase 2 data from the ROSETTA-Lung-02 study, where Pumitamig goes head-to-head against pembrolizumab plus chemotherapy — the established first-line standard for non-small cell lung cancer. A convincing showing in this direct comparison would mark the first real proof that the oncology strategy is delivering.

Pumitamig’s development is accelerating. In partnership with Bristol Myers Squibb, five additional registrational studies for the drug candidate were launched this year.

BioNTech at a turning point? This analysis reveals what investors need to know now.

Gotistobart, meanwhile, has already generated encouraging signals. Non-pivotal data showed a 54% reduction in the risk of death versus docetaxel in squamous cell lung carcinoma, though the sample size was small. Validation will come from interim Phase 3 data expected later in 2026. In total, BioNTech has promised six clinical data packages this year, with ASCO serving as the curtain-raiser.

A separate catalyst could arrive by the third quarter, when a milestone payment of €613 million from a collaboration is expected to bolster the revenue line. For now, all eyes are on Chicago at the end of May.

Ad

BioNTech Stock: New Analysis - 8 May

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

en | US09075V1026 | BIONTECH’S | boerse | 69295452 |